Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Sosipatros A. Boikos

Hematology Oncology | Hematology | Oncology
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sosipatros Boikos is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Boikos is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Synovial Sarcoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Languages Spoken
English
Greek
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

1250 E Marshall St, Internal Medicine, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer
A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

47 Total Publications

Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma.
Journal: JCO precision oncology
Published: July 02, 2025
Similar Doctors
Renato G. Martins
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Renato G. Martins
Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Renato G. Martins
Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (1.9 miles away)
804-828-7929
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Renato Martins is an Oncologist in Richmond, Virginia. Dr. Martins is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Salivary Gland Tumors, and EGFR Positive Lung Cancer. Dr. Martins is currently accepting new patients.

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Majd Issa
Hematology Oncology | Hematology | Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Majd Issa
Hematology Oncology | Hematology | Oncology

Hematology-Oncology Associates Of Fredericksburg Inc

4545 Empire Ct, 
Fredericksburg, VA 
 (47.0 miles away)
540-371-0079
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Majd Issa is a Hematologist Oncology specialist and a Hematologist in Fredericksburg, Virginia. Dr. Issa is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Thrombocytopenia, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Endoscopy. Dr. Issa is currently accepting new patients.

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Erin R. Alesi
Hematology Oncology | Hematology | Oncology
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Erin R. Alesi
Hematology Oncology | Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (1.9 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Alesi is a Hematologist Oncology specialist and a Hematologist in Richmond, Virginia. Dr. Alesi is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Laryngeal Cancer, Lung Cancer, Small Cell Lung Cancer (SCLC), Gastrostomy, and Bone Marrow Aspiration. Dr. Alesi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boikos's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 104 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile